| Basics |
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
|
| IPO Date: |
July 24, 1991 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$115.56B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.83 | 1.67%
|
| Avg Daily Range (30 D): |
$4.70 | 1.10%
|
| Avg Daily Range (90 D): |
$4.86 | 1.19%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.59M |
| Avg Daily Volume (30 D): |
1.09M |
| Avg Daily Volume (90 D): |
1.39M |
| Trade Size |
| Avg Trade Size (Sh.): |
92 |
| Avg Trade Size (Sh.) (30 D): |
26 |
| Avg Trade Size (Sh.) (90 D): |
31 |
| Institutional Trades |
| Total Inst.Trades: |
30,210 |
| Avg Inst. Trade: |
$8.56M |
| Avg Inst. Trade (30 D): |
$36.7M |
| Avg Inst. Trade (90 D): |
$29.34M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
5 |
| Market Closing Trades |
| Avg Closing Trade: |
$31.56M |
| Avg Closing Trade (30 D): |
$107.53M |
| Avg Closing Trade (90 D): |
$98.84M |
| Avg Closing Volume: |
145.29K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$14.3
|
$4.24
|
$4.02
|
|
Diluted EPS
|
$14.21
|
$4.2
|
$3.99
|
|
Revenue
|
$ 11.72B
|
$ 3.08B
|
$ 2.96B
|
|
Gross Profit
|
$ 10.11B
|
$ 2.66B
|
$ 2.56B
|
|
Net Income / Loss
|
$ 3.68B
|
$ 1.08B
|
$ 1.03B
|
|
Operating Income / Loss
|
$ 3.99B
|
$ 1.19B
|
$ 1.15B
|
|
Cost of Revenue
|
$ 1.61B
|
$ 414.8M
|
$ 407.5M
|
|
Net Cash Flow
|
$ -300.3M
|
$ -34.2M
|
$ 296.6M
|
|
PE Ratio
|
31.35
|
|
|
|
|
|
